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KEYWORDS	
	 New	benzimidazole	derivatives,	namely,	(N‐(4‐methoxyphenyl)methylene]‐1H‐benzimidazol‐
2‐amine	 (2a),	 (N‐(3,4‐dimethoxyphenyl)methylene]‐1H‐benzimidazol‐2‐amine	 (2b),	 and	 (N‐
(3,4,5‐trimethoxyphenyl)methylene]‐1H‐benzimidazol‐2‐amine	 (2c)	 were	 synthesized	 by
reaction	of	a	Schiff	base	with	malononitrile	in	absolute	ethanol.	Structures	of	compounds	have
been	 confirmed	 by	 IR,	 1H	NMR	 and	 elemental	 analysis.	 Compounds	 2a‐c	were	 screened	 for
their	 in	vitro	 anticancer	 potential	 using	HeLa	 and	PC3	 cells.	All	 compounds	 showed	 limited
cytotoxicity	except	compound	2a	that	showed	a	moderate	cytotoxic	effect	towards	HeLa	cells.	
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1.	Introduction	
	
Cancer	 is	 the	 biggest	 health	 issue	 in	 the	 world.	 Cancer	
developed	 resistance	 against	 many	 existing	 anticancer	 drugs.	
This	 keeps	 a	 research	 window	 open	 in	 search	 for	 newer	
anticancer	molecules.	However,	it	is	rather	difficult	to	come	up	
with	a	molecule	that	can	selectively	inhibit	the	proliferation	of	
abnormal	 cells	 only	 with	 least	 or	 no	 effect	 on	 normal	 cells.	
Many	 authors	 worldwide	 have	 studied	 benzimidazole.	 A	
potential	of	antitumor,	anti‐proliferative	or	anticancer	has	been	
reported	[1‐4].	
Benzimidazole	nucleus	has	been	confirmed	as	an	important	
pharmacophore	in	drug	discovery	[5].	Its	derivatives	have	been	
reported	 to	 exhibit	 antitumor	 [6],	 antibacterial	 [7],	 anti‐
inflammatory	 [8]	 and	 promising	 anticancer	 activities	 [9‐10].	
Moreover,	 benzimidazoles	 have	 been	 used	 as	 biomimetic	 of	
guanine	 residues	 [11]	 and	 they	 selectivity	 inhibit	 endothelial	
cell	growth	and	suppress	angiogenesis	in	vivo	and	in	vitro	[12].	
Due	 to	 a	 broad	 spectrum	 of	 activities	 noted	 so	 far	 and	 in	
continuation	 of	 our	 research	 interest	 on	 the	 synthesis	 of	
bioactive	heterocycles,	we	describe	here	the	synthesis	of	cyclic	
benzimidazole	derivatives	and	study	their	anticancer	effect.	
		
2.	Experimental	
	
2.1.	Chemicals	
	
2‐Aminobenzimidazole,	 4‐methoxybenzaldehyde,	 3,4,5‐
trimethoxybenzaldehyde,	 3,4‐dimethoxybenzaldehyde,	 piperi‐
dine	 and	 malononitrile	 were	 obtained	 commercially	 from	
Aldrich	and	Fluka	Chemicals.	Solvents	were	reagent	grade	and	
were	used	as	received:	dry	absolute	ethanol,	petroleum	ether,	
n‐hexane	 and	 ethyl	 acetate.	 Progress	 of	 reactions	 was	
monitored	 by	 thin	 layer	 chromatography	 (TLC)	 using	
precoated	 aluminum	 sheet	 silica	 gel;	 Merck	 60	 F254	 and	 was	
visualized	by	UV	lamp.	
	
2.2.	Instrumentations	
	
Melting	 points	 were	 measured	 on	 an	 electrothermal	
melting	 point	 apparatus	 and	 were	 not	 corrected.	 Fourier‐
transform	 infrared	 spectra	 were	 recorded	 using	 the	 KBr	 disc	
technique	on	a	JASCO	410	FTIR	spectrophotometer.	Elemental	
(CHN)	 analysis	 was	 performed	 using	 an	 Exeter	 CE‐440	
elemental	 analyzer.	 1H	 NMR	 spectra	 of	 the	 compounds	 were	
recorded	 on	 a	 Varian	 Gemini‐200	 spectrometer	 (200	 MHz)	
using	 DMSO‐d6	 as	 solvent	 and	 TMS	 as	 internal	 reference.	
Anticancer	 activity	 was	 evaluated	 at	 the	 International	 Center	
for	 Chemical	 Sciences	 and	 Dr.	 Panjwani	 Center	 for	 Molecular	
Medicine	and	Drug	Research,	University	of	Karachi,	Pakistan.	
	
2.3.	Synthesis	of	Schiff	base	ligands	
	
Syntheses	of	Schiff	base	compounds	1a‐c	were	carried	out	
through	 the	 method	 described	 by	 Nawrocka	 et	 al.	 [13]	
involving	 the	 condensation	 of	 an	 equimolar	 mixture	 of	 2‐
aminobenzimidazole	 (0.01	 mol)	 and	 the	 aldehyde	 as	 3,4,5‐
trimethoxybenzaldehyde	 (0.01	 mol),	 3,4‐dimethoxybenz‐
aldehyde	 (0.01	mol)	 and	 4‐methoxybenzaldehyde	 (0.01	mol),	
respectively,	 in	ethanol	(25	mL).	The	mixture	was	refluxed	for	
24	 hours	 under	 nitrogen	 atmosphere.	 Schiff	 base	 compounds	
formed	were	isolated	by	crystallization	from	a	suitable	solvent.	
	
2.4.	Synthesis	of	cyclic	benzimidazole	
	
Schiff	 base	 compounds	 (0.01	 mol)	 were	 reacted	 with	
malanonitrile	(0.01	mol)	 in	ethanol	with	a	catalytic	amount	of	
piperidine	 (0.2	 mL).	 The	 reaction	 mixture	 was	 heated	 under	
reflux	for	4	hrs.		
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Scheme	1
	
	
Then	 the	 reaction	mixture	 was	 poured	 onto	 crushed	 ice	 and	
neutralized	by	hydrochloric	acid	to	give	a	crude	product	which	
was	 filtered	 off,	 washed	 several	 times	with	 cold	 water,	 dried	
and	crystallized	(Scheme	1).	
4‐Amino‐2‐(4‐methoxyphynyl)benzo[4,5]imidazo[1,2‐a]	
pyrimidine‐3‐carbonitrile	 (2a):	 Yellow	 crystals,	 recrystallized	
from	ethanol.	Yield:	35%.	M.p.:	103‐105	oC.	FT‐IR	(KBr,	,	cm‐1):	
3367	 (NH2)	 (amine),	 2222	 (CN)	 (cyano),	 1645,	 1605	 (C=N)	
(pyrimidine	 and	 imidazole),	 1571	 (C=C)	 (aromatic).	 1H	 NMR	
(200	MHz,	DMSO	d6,	δ,	ppm):	3.90	(s,	3H,	OCH3,),	6.90‐8.40	(m,	
8H,	 Ar‐H,	 NH2).	 Anal.	 calcd.	 for	 C18H13N5O:	 C,	 68.6;	 H,	 4.2;	 N,	
22.2.	Found:	C,	68.9;	H,	3.9;	N,	21.9%.	
4‐Amino‐2‐(3,4‐dimethoxyphenyl)benzo[4,5]imidazo[1,2‐a]	
pyrimidine‐3‐carbonitrile	 (2b):	 Dark	 Yellow	 crystals,	
recrystallized	from	ethanol.	Yield:	30%.	M.p.:	143‐144	oC.	FT‐IR	
(KBr,	,	 cm‐1):	 3372	 (NH2)	 (amine),	 2222	 (CN)	 (cyano),	 1642,	
1600	 (C=N)	 (pyrimidine	 and	 imidazole),	 1581	 (C=C)	
(aromatic).	 1H	NMR	(200	MHz,	DMSO	d6,	 δ,	ppm):	3.80	(s,	3H,	
OCH3),	 3.89	 (s,	 3H,	OCH3),	 7.15‐8.16	 (m,	 9H,	Ar‐H,	NH2).	Anal.	
calcd.	for	C19H15N5O2:	C,	66.1;	H,	4.4;	N,	20.3.	Found:	C,	62.9;	H,	
4.3;	N,	19.8%.	
4‐Amino‐2‐(3,4,5‐trimethoxyphenyl)benzo[4,5]imidazo[1,2‐
a]	pyrimidine‐3‐carbonitrile	(2c):	Yellow	crystals,	recrystallized	
from	n‐hexane‐ethyl	acetate.	Yield:	35%.	M.p.:	117‐120	oC.	FT‐
IR	(KBr,	,	cm‐1):	3397	(NH2)	(amine),	2224	(CN)	(cyano),	1647,	
1600	 (C=N)	 (pyrimidine	 and	 imidazole),	 1582	 (C=C)	
(aromatic).	1H	NMR	(200	MHz,	DMSO‐	d6,	δ,	ppm):	3.99	(s,	6H,	
OCH3),	 3.82	 (s,	 3H,	OCH3,)	 6.87‐8.43	 (m,	 8H,	Ar‐H,	NH2).	Anal.	
calcd.	for	C20H17N5O3:	C,	64.0;	H,	4.6;	N;	18.7.	Found:	C,	62.4;	H,	
4.5;	N,	19.5%.	
	
2.5.	Cytotoxicity		
	
Cytotoxic	 activity	 of	 compounds	was	 evaluated	 in	 96‐well	
flat‐bottomed	microplates	by	using	 the	standard	MTT	 (3‐[4,5‐
dimethylthiazole‐2‐yl]‐2,5‐diphenyl‐tetrazolium	 bromide)	
colorimetric	 assay	 [14].	 For	 this	 purpose,	 PC‐3	 cells	 (Prostate	
Cancer)	 and	 HeLa	 cells	 were	 cultured	 in	 Dulbecco’s	 Modified	
Eagle’s	 Medium,	 and	 Minimal	 Essential	 Medium	 (MEM),	
supplemented	with	5%	of	fetal	bovine	serum	(FBS),	100	IU/mL	
of	 penicillin	 and	 100	 µg/mL	 of	 streptomycin	 in	 25	 cm3	 flask,	
and	kept	 in	5%	CO2	 incubator	at	37	oC.	Exponentially	growing	
cells	 were	 harvested,	 counted	 with	 haemocytometer	 and	
diluted	 with	 a	 particular	 medium.	 Cell	 culture	 with	 the	
concentration	of	1x105	cells/mL	was	prepared	and	introduced	
(100	 µL/well)	 into	 96‐well	 plates.	 After	 overnight	 incubation,	
medium	was	removed	and	200	µL	of	fresh	medium	was	added	
with	different	concentrations	of	compounds	(1‐100	µM).	After	
48	 h,	 50	 µL	 MTT	 (2	 mg/mL)	 was	 added	 to	 each	 well	 and	
incubated	 further	 for	 4	hours.	 Subsequently,	 100	µL	of	DMSO	
was	 added	 to	 each	 well.	 The	 extent	 of	 MTT	 reduction	 to	
formazan	 within	 cells	 was	 calculated	 by	 measuring	 the	
absorbance	at	570	nm,	using	a	micro	plate	reader	(Spectra	Max	
plus,	 Molecular	 Devices,	 Ca,	 USA).	 The	 cytotoxicity	 was	
recorded	 as	 concentration	 causing	 50%	 growth	 inhibition	
(IC50).	
	
3.	Results	and	discussion	
	
3.1.	Synthesis	and	characterization	
	
Schiff	base	compounds	(1a‐c)	was	prepared	by	reaction	of	
2‐aminobenzimidazole	 with	 4‐methoxybenzaldehyde,	 3,4‐
dimethoxybenzaldehyde	 and	 3,4,5‐trimethoxybenzaldehyde,	
respectively,	in	refluxing	solvent	(Scheme	1).		
Schiff	base	compounds	1a‐c	 (0.01	mol)	were	 reacted	with	
malononitrile	(0.01	mole)	to	give	2a‐c	compounds	(Scheme	1).	
Structures	of	compounds	were	confirmed	on	the	basis	of	their	
elemental	analysis	and	spectral	data.	
IR	 spectra	 of	 compounds	 2a‐c	 showed	 absorption	 bands	
characteristic	 for	NH2	at	3367,	3372	and	3397	cm‐1	and	CN	at	
2222,	 2222	 and	 2224	 cm‐1,	 respectively.	 1H	 NMR	 spectra	
showed	multiple	signals	around	7.00‐8.40,	7.18‐8.16,	and	6.80‐
8.40	ppm,	ascribed	to	aromatic	and	NH2	protons.	
	
3.2.	Anticancer	activity	
	
Results	 of	 in	 vitro	 anticancer	 activity	 of	 the	 tested	
compounds	 2a‐c	 were	 evaluated	 for	 cytotoxicity	 against	 PC3	
cells	and	Hela	cells	of	humans	in	comparison	with	doxorubicin	
as	 a	 positive	 control.	 All	 tested	 compounds	 showed	 a	 limited	
cytotoxic	 activity	 except	 compound	2a	 that	 showed	moderate	
cytotoxic	 effect	 towards	 Hela	 cells.	 Table	 1	 represents	 the	
cytotoxic	activity	of	the	tested	compounds.		
	
Table	1.	 Cytotoxic	 activity	 of	 compounds	2a‐c	 against	HeLa	 Cells	 and	 PC3	
Cells.		
Compound	
PC3 HeLa	
IC50	±	SD*	(μM)	 IC50	±	SD	(μM)	
2a >50 22.57	±	0.16
2b >50 >50	
2c >50 >50	
Doxorubicin	(as	control)	 0.912	±	0.120	 3.10	±	0.20	
*	SD:	Standard	deviation.	
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4.	Conclusion	
	
The	 present	 work	 describes	 the	 synthesis	 and	 in	 vitro	
anticancer	evaluation	of	some	cyclic	benzimidazole	derivatives	
2a‐c.	Most	 of	 the	 tested	 compounds	 showed	 limited	 cytotoxic	
activity	except	compound	2a	that	showed	a	moderate	cytotoxic	
effect	towards	Hela	cells.	
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